- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02774980
Cognitive Markers of Response to Treatment in Resistant Depression (DEP-ICOR)
Patients with depression are frequently treatment resistant. Clinical manifestations of depression are various, but cognitive dysfunctions are commonly present. Many factors are involved in treatment resistance. As no biological marker is available, clinical markers could be considered in predicting response to antidepressive treatment.
The aim of this study is to investigate the relation between the cognitive changes and the remission of depressive symptoms in patients with recurrent depression (Stage 2 of Thase and Rush classification).
To explore the dynamics of cognitive dimension associated to clinical and functional remission, the investigators will observe neurocognitive functioning before and after introducing a new antidepressive therapy.
연구 개요
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
-
Nice, 프랑스, 06000
- Hôpital Pasteur
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Patients will be aged from 40 to 70, with a major depressive episode diagnosis with a 2 stage degree of resistance.
Exclusion Criteria:
- Patients with major depressive episode during more of 12 months
- Alzheimer dementia or related disease (CIM 10)
- Score Hamilton Depression Rating Scale (HDRS) < 18
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Clinic assessments: Score BDI - II
기간: Change from the baseline score BDI-II at 12 months after introducing the new therapy
|
The investigators will conduct clinical assessments.
A baseline will be drawn in the acute phase (V1) before modifying the antidepressive therapy; 2 weeks after treatment change, patient will be clinically assessed by his psychiatrist.
A complete assessment will be done 6 months and 12 months after introducing the new therapy.
|
Change from the baseline score BDI-II at 12 months after introducing the new therapy
|
|
Functional assessments : Score Sheehan Disability Scale (SDS)
기간: Change from the baseline Score Sheehan Disability Scale (SDS) at 12 months after introducing the new therapy
|
The investigators will conduct functional assessments.
A baseline will be drawn in the acute phase (V1) before modifying the antidepressive therapy; 2 weeks after treatment change, patient will be functional assessed by his psychiatrist.
A complete assessment will be done 6 months and 12 months after introducing the new therapy.
|
Change from the baseline Score Sheehan Disability Scale (SDS) at 12 months after introducing the new therapy
|
|
Neuropsychologic assessments: M.M.S.E. (Mini Mental Score Evaluation)
기간: Change from the baseline Score M.M.S.E. (Mini Mental Score Evaluation) at 12 months after introducing the new therapy
|
The investigators will conduct neuropsychologic assessments.
A baseline will be drawn in the acute phase (V1) before modifying the antidepressive therapy; A complete assessment will be done 6 months and 12 months after introducing the new therapy.
|
Change from the baseline Score M.M.S.E. (Mini Mental Score Evaluation) at 12 months after introducing the new therapy
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Nelly Darmon, CHU of Nice
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정된)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .